Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company specializing in rare and serious conditions and plasma-derived products, has announced its upcoming financial results release. The company will disclose its second quarter and first half 2024 financial results on August 14, 2024, before U.S. financial markets open.
Following the release, Kamada's management will host an investment community conference call at 8:30am Eastern Time on the same day. Shareholders and interested parties can participate via phone or webcast. The call will be archived on the company's website for 90 days.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), una società biofarmaceutica globale in fase commerciale specializzata in condizioni rare e gravi e prodotti derivati dal plasma, ha annunciato la prossima pubblicazione dei risultati finanziari. L'azienda divulguerà i suoi risultati finanziari del secondo trimestre e del primo semestre 2024 il 14 agosto 2024, prima dell'apertura dei mercati finanziari statunitensi.
Dopo la pubblicazione, la direzione di Kamada terrà una conference call con la comunità degli investitori alle 8:30 ora orientale dello stesso giorno. Gli azionisti e le parti interessate possono partecipare via telefono o webcast. La registrazione della chiamata sarà archiviata sul sito web dell'azienda per 90 giorni.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), una compañía biofarmacéutica global en etapa comercial que se especializa en condiciones raras y graves y productos derivados del plasma, ha anunciado la próxima publicación de sus resultados financieros. La empresa revelará sus resultados financieros del segundo trimestre y del primer semestre de 2024 el 14 de agosto de 2024, antes de la apertura de los mercados financieros en EE. UU.
Después de la publicación, la dirección de Kamada llevará a cabo una llamada de conferencia para la comunidad de inversores a las 8:30 a.m. hora del Este el mismo día. Los accionistas y partes interesadas pueden participar por teléfono o por webcast. La llamada será archivada en el sitio web de la empresa durante 90 días.
카마다(NASDAQ: KMDA; TASE: KMDA.TA)는 상업 단계의 글로벌 생명공학 회사로서 희귀 및 중증 질환과 혈장 유래 제품을 전문으로 하며, 곧 재무 실적 발표 예정임을 알렸습니다. 이 회사는 2024년 2분기 및 상반기 재무 실적을 2024년 8월 14일에 미국 금융 시장이 열리기 전에 공개할 예정입니다.
발표 후, 카마다 경영진은 같은 날 동부 표준시 기준 오전 8시 30분에 투자 커뮤니티 컨퍼런스 콜를 개최합니다. 주주 및 관심 있는 당사자들은 전화 또는 웹캐스트를 통해 참여할 수 있습니다. 이 통화는 회사 웹사이트에 90일 동안 보관됩니다.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), une entreprise biopharmaceutique mondiale en phase commerciale spécialisée dans les maladies rares et graves ainsi que les produits dérivés du plasma, a annoncé la prochaine publication de ses résultats financiers. La société révélera ses résultats financiers du deuxième trimestre et du premier semestre 2024 le 14 août 2024, avant l'ouverture des marchés financiers américains.
Suite à cette annonce, la direction de Kamada animera une conférence téléphonique avec la communauté des investisseurs le même jour à 8h30, heure de l'Est. Les actionnaires et les parties intéressées pourront participer par téléphone ou par webinaire. L'appel sera archivé sur le site web de l'entreprise pendant 90 jours.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), ein globales biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf seltene und schwere Erkrankungen sowie plasma-abgeleitete Produkte spezialisiert hat, hat die bevorstehende Veröffentlichung seiner finanziellen Ergebnisse angekündigt. Das Unternehmen wird am 14. August 2024 vor Eröffnung der US-Finanzmärkte seine Finanzergebnisse für das zweite Quartal und das erste Halbjahr 2024 veröffentlichen.
Nach der Veröffentlichung wird das Management von Kamada am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz für die Investoren-Community abhalten. Aktionäre und interessierte Parteien können telefonisch oder per Webcast teilnehmen. Die Aufzeichnung des Anrufs wird 90 Tage lang auf der Unternehmenswebsite archiviert.
- None.
- None.
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second quarter and first half ended June 30, 2024, prior to the open of the U.S. financial markets on Wednesday, August 14, 2024.
Kamada management will host an investment community conference call on Wednesday, August 14 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.) or 1-809-406-247 (from Israel) or 1-201-689-8263 (International) using conference ID 13747542. The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1678713&tp_key=b3f21d48c3
The call will also be archived for 90 days on the Company’s website at www.kamada.com.
About Kamada
Kamada Ltd. (the “Company”) is a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company’s strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical fields. The Company’s commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: KEDRAB®, CYTOGAM®, WINRHO SDF®, VARIZIG®, HEPAGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India Australia and other countries in Latin America, Europe, the Middle East, and Asia. The Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers. During recent years the Company added eleven biosimilar products to its Israeli distribution portfolio, which, subject to European Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the manufacture of KAMRHO (D), KAMRAB and KEDRAB. In addition to the Company’s commercial operation, it invests in research and development of new product candidates. The Company’s leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
(212) 915-2578
britchie@LifeSciAdvisors.com
FAQ
When will Kamada (KMDA) release its Q2 and H1 2024 financial results?
How can investors participate in Kamada's (KMDA) Q2 2024 earnings call?
Where can I find the archived version of Kamada's (KMDA) Q2 2024 earnings call?
